25
Participants
Start Date
October 5, 2021
Primary Completion Date
August 1, 2025
Study Completion Date
December 1, 2025
Ipilimumab
1mg/kg IV on day 1 (1 dose total)
Nivolumab
3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
SBRT
1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
RECRUITING
Rhode Island Hospital, Providence
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Brown University
OTHER